All posts by imreal

FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to Enable GMP Manufacturing of Cell and Exosome Therapies


“Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to partner with FUJIFILM Diosynth Biotechnologies to translate our MSC and exosome technologies into advanced therapy products for patients around the world.” – Tim Kelly, CEO, RoosterBio

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today a strategic collaboration with RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services. Through this collaboration, FUJIFILM Diosynth Biotechnologies will incorporate RoosterBio’s industry-leading process development technology for both MSC and extracellular vesicle (EV) / exosome programs into its manufacturing capabilities and offerings.

This collaboration offers biopharma customers an end-to-end solution for development and production of MSC and exosome therapeutics, allowing for seamless transition of programs from RoosterBio’s process and analytical development services into FUJIFILM Diosynth Biotechnologies’ advanced therapies GMP capabilities. Manufacturing services and expertise provided by FUJIFILM Diosynth Biotechnologies will include cell expansion and collection of MSCs, downstream processing for exosome purification, and drug product manufacturing. Terms of the agreement were not disclosed.

“This collaboration will enable us to become a fully integrated cell therapy CDMO partner to our biopharma customers,” said Gerry Farrell, chief operating officer, FUJIFILM Diosynth Biotechnologies, Texas and California. “MSC products are known to have great potential in areas such as regenerative medicine and immune system modulation. In addition, exosomes are attractive as drug delivery vehicles as well as therapeutics. The partnership is aligned with our core purpose of advancing tomorrow’s medicines by enabling the advancement of our customer’s pipelines in this space.”

“FUJIFILM Diosynth Biotechnologies is a global leader in the manufacturing of advanced therapies and is creating the industry’s largest network of biologics CDMO facilities,” said Tim Kelly, chief executive officer, RoosterBio. “Biopharmaceutical companies striving to develop engineered cell and exosome therapies require proven, flexible technologies paired with reliable and scalable manufacturing capabilities. Through this collaboration, we will deliver that comprehensive solution to our customers, and I am delighted to partner with FUJIFILM Diosynth Biotechnologies to translate our MSC and exosome technologies into advanced therapy products for patients around the world.”

About RoosterBio

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year. RoosterBio is driven by clients’ success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

http://www.roosterbio.com

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. The company operates a global network with major locations in the Unites States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies’ UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites.

For more information, go to: http://www.fujifilmdiosynth.com

About FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2022, the company had global revenues of approximately 2.5 trillion yen (21 billion $USD at an exchange rate of 122 yen/dollar).

For more information, please visit: http://www.fujifilmholdings.com

Share article on social media or email:

Clean Beauty Brand Aloette Announces Party with Purpose Charity Incentive for Mental Health Awareness Month


“I am thrilled that Aloette and our entire field have come together to draw awareness and support to this very important issue,” says President of Aloette, Cathy McKenna. “We are hoping for a tremendous week so that we can really give back to our community.”



Aloette, an industry leader in providing clean beauty solutions that are gentle for skin and the environment, is announcing an exciting charity incentive for Mental Health Awareness Month. From October 23rd-October 31st, Aloette will be donating a portion of all party sales to organizations in the US and Canada that address the mental health issues that women face throughout their lifetime. Aloette says their goal is to raise awareness and help stop the stigma associated with asking for help with mental health issues.

“I am thrilled that Aloette and our entire field have come together to draw awareness and support to this very important issue,” says President of Aloette, Cathy McKenna. “We are hoping for a tremendous week so that we can really give back to our community.”

Research states that 1 in 5 women experience a common mental health disorder at least once in their lifetime. Aloette wants to be a part of the solution to expand knowledge, treatment, compassion, and understanding to those dealing with mental health issues. The beauty and skincare brand has asked both customers and consultants to help raise funds for the cause in the following ways:

Consultants: Book Aloette parties both in person and virtually to help raise funds for the cause. Consultants are encouraged to share personal stories, if comfortable, or facts related to mental health issues on social media using Aloette graphics as well as creating personal content regarding mental health.

Customers: Host a party from October 23rd-October 31st and a position of sales will be donated to the charity Aloette is supporting. As a special thank you, Aloette will be giving customers one of the new Jetsetter Palette’s for $10 for those hosting a party during the last week of October 2022.

Other ways that Aloette fans can help is by making an independent donation to the organizations Aloette supports, such as Canadian Mental Health Association (CMHA) and Seek Her Foundation in the US, or other outside mental health organizations. Aloette also encourages others to join “The Hub,” Aloette’s Facebook group, to share mental health stories with Aloette’s supportive community. Customers and consultants at Aloette agree that women are #BetterTogether regarding promoting and raising awareness for mental health struggles, and those at Aloette are excited to help stop the stigma regarding mental health.

About Aloette

Aloette is North America’s premier age-defying beauty brand, providing women of all ages and origins with the high-quality skin care and cosmetic products and home-based business opportunities in the health and beauty industry. Incorporating clean and cutting-edge cosmetic ingredients and technology, Aloette offers an array of high-performance makeup and skin care solution lines designed to help deliver real results. Aloette Cosmetics is an Astral Brands company. For more information, visit http://www.aloette.com.

Share article on social media or email:

New fertility study by Shady Grove Fertility (SGF) provides hope for those diagnosed with cancer


Shady Grove Fertility’s research team presented an award-winning study at ASRM 2022 that can provide reassurance for patients undergoing fertility preservation treatment following a cancer diagnosis.

“At SGF, we know the importance of innovative, evidence-based fertility care. With this new information, we can better counsel patients and reassure them that their cancer diagnosis does not have to mean the end of their family-building dreams.”

New research from Shady Grove Fertility (SGF), conducted with the University of Colorado School of Medicine and the School of Public Health, has shown that patients with a recent cancer diagnosis can expect comparable results from fertility preservation treatment to those who are undergoing elective egg-freezing.

Presented this week at the 78th ASRM Scientific Congress & Expo in Anaheim, California, the study was selected as the Fertility Preservation Special Interest Group Prize Paper. The study, Ovarian Response and Anti-Mullerian Hormone in Fertility Preservation Versus Elective Oocyte Cryopreservation Cycles: A Society for Assisted Reproductive Technology Registry Study of 10,040 Cycles, was conducted by Ivy Lersten, M.D., University of Colorado School of Medicine and SGF fellow; Angela J. Fought, University of Colorado School of Public Health; and Cassandra Roeca, M.D., SGF physician who sees patients at SGF Colorado’s Denver location.

This national retrospective cohort study of ovarian response and anti-Mullerian hormone (AMH) in cancer patients undergoing fertility preservation treatment compared to patients who are electively freezing their eggs looked at data from 10,040 cycles from the Society for Assisted Reproductive Technology (SART) registry and found the relationship between the number of eggs retrieved or cryopreserved and AMH did not differ for fertility preservation versus elective egg freezing groups.    

“The relationship between AMH levels and ovarian response to fertility treatment is well established,” shares Dr. Roeca. “We wanted to investigate whether this relationship is preserved for patients with a recent cancer diagnosis.”

The study concludes that the relationship between retrieved and frozen eggs, as well as AMH levels, for cancer patients undergoing fertility preservation treatment are comparable to those who are electively freezing their eggs. This new information can provide additional reassurance for patients with cancer who are planning to have biological children in the future.

“At SGF, we know the importance of innovative, evidence-based fertility care,” adds Dr. Roeca. “With this new information, we can better counsel patients and reassure them that their cancer diagnosis does not have to mean the end of their family-building dreams.”

SGF is one of only a few private practice fertility centers in the country to employ a full-time dedicated research team, which operates under Director of Research, Kate Devine, M.D., a board certified reproductive endocrinologist who sees patients at SGF’s Washington, D.C., K Street location. Dr. Devine also serves as the Executive Medical Director and Chief Research Officer at US Fertility, the largest network of physician-owned and physician-led fertility practices in the United States, of which SGF is a founding partner practice.

To best serve patients newly diagnosed with cancer, SGF works closely with patients and their cancer team to ensure that all patients interested in fertility preservation will receive an immediate consultation and best preservation options based on their cancer treatment plan.

As a premier IVF and fertility center of excellence, SGF continues to make a sustained commitment to clinical research and educating physicians in training.

To learn more about ongoing research being conducted at SGF, visit http://www.shadygrovefertility.com/research.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 50 locations, including the newest location in Raleigh, North Carolina, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Share article on social media or email:

MCG Partners with MultiCare to Reduce Prior Authorization Burden


MCG Health

MCG Health, part of the Hearst Health network

“Through this innovative approach, MCG can help MultiCare automate evidence-based decision-making within their existing clinical workflow.” – Jon Shreve, MCG President and CEO

MCG Health, part of the Hearst Health network and an industry leader in evidence-based guidance, announces the nation’s first implementation of a prior authorization automation solution between a payer, provider, and technology vendor using the HL7® Da Vinci Project FHIR (Fast Healthcare Interoperability Resources) standard.

MCG and MultiCare Connected Care collaborated successfully to use MCG’s interoperable application to surface and automate clinical requirements for prior authorization requests natively from electronic health records (EHR) at the point of care to payers using HL7 FHIR standards. With real-time data exchange and communications, the solution is expected to significantly reduce authorization decision times to support timely patient treatment, alleviate administrative burden for both hospitals and health plan staff, and decrease the overall costs of care delivery.

MCG and MultiCare are members of the HL7® Da Vinci Project, a national, private sector initiative to accelerate the use of HL7® FHIR to enable value-based care through interoperable data. MultiCare is utilizing the MCG Authorization application to surface transparent policy requirements and automate the retrieval of clinical data needed to establish coverage within the payer and provider workflow. MCG used the Da Vinci Implementation Guide (IG) for Documentation Templates and Rules (DTR) to accomplish the transparency and automation requirements.

“This implementation marks a new era for patient treatment and is a sterling example of successful industry collaboration,” said MCG President and CEO, Jon Shreve. “Through this innovative approach, MCG can help MultiCare automate evidence-based decision-making within their existing clinical workflow. The results of this endeavor will provide far-reaching benefits to hospitals, health plans, and most importantly, the patient.”

For more information on the MCG solution pivotal to this implementation, visit https://appmarket.epic.com/Gallery?id=13309.

###

About MCG Health

MCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG’s artificial intelligence and technology, infused with clinical expertise, enables its clients to prioritize and simplify their work. MCG’s world-class customer service ensures that clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes. For more information visit http://www.mcg.com or follow our Twitter handle at @MCG_Health.

About MultiCare Connected Care

MultiCare Connected Care (MCC) is an independent Accountable Care Organization (ACO) established in 2014 as a wholly owned subsidiary of MultiCare Health System and operates as an independent entity. It is transforming healthcare as a population health engine that represents a Clinically Integrated network (CIN) of independent & MultiCare Health System clinicians services across the entire social medical model of care. Under this entity 350,000 lives are served within 30 value based contracts.

Unlike the traditional “fee for service” health care model – where each visit, service, test and procedure has a separate cost – MCC‘s foundation is built first and foremost on providing patient centered quality care at an appropriate cost. Specific measures are used to determine how well doctors, hospitals and other providers are keeping healthy people healthy, effectively treating illnesses, and helping people better manage their chronic conditions. In this way, all the participating providers share the responsibility of providing patient centered, high quality, efficient, cost-effective care.

MCC has established a comprehensive Clinically Integrated Network (CIN) comprised of doctors and other health care providers, as well as hospitals, clinics and other health care services, such as imaging, labs and pharmacies. The CIN includes independent health care professionals in the community, as well as MultiCare employed providers totaling over 5,100 clinicians providing services across the continuum of care.

multicareconnectedcare.com

About the HL7 Da Vinci Project

As an HL7 FHIR Accelerator, the Da Vinci Project is a private sector initiative comprised of industry leaders and health information technology technical experts who are working together to accelerate the adoption of HL7® FHIR® as the standard to support and integrate value-based care (VBC) data exchange across communities. The Da Vinci Project focuses on minimizing the development and deployment of one-off solutions between partners with a goal to help all clinicians and health plans to better deliver clinical quality, value and care management outcomes. The core focus of phase one of the project is to deliver implementation guides and reference software implementations to the public for data exchange and workflows necessary to support providers and payers entering and managing VBC contracts and relationships. To learn more about the Da Vinci Project, visit https://confluence.hl7.org/display/DVP/Da+Vinci+Welcome.

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Care guidance from Hearst Health reaches the majority of people in the U.S. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.

Share article on social media or email:



Essex County Pediatric Cardiologist, Dr. Donald Putman Awarded NJ Top Doc


Dr. Donald Putman

Dr. Donald Putman

NJ Top Docs has reviewed and selected Donald Putman, MD for 2022. Dr. Putman is a board certified cardiologist with RWJBarnabas Health Medical Group in Livingston, New Jersey.

“As a pediatric cardiologist dedicated to my patients, I take pride in not just the care of my patients but availability and rapid responsiveness to my colleagues and referring physicians,” says Dr. Putman.

Dr. Putman is Division Chief of Pediatric Cardiology at Cooperman Barnabas Medical Center in Livingston and Director of Cardiac Screening for the Matthew J. Morahan lll Health Assessment Center.

Dr. Putman offers pediatric cardiology consultations for fetal echocardiography, congenital heart disease and suspected acquired heart disease in infants, children, adolescents and young adults.

He is continually recognized for delivering exemplary care with an upbeat engaging approach.

To learn more about NJ Top Doc Dr. Donald Putman please visit: https://njtopdocs.com/nj-doctors/metropediatriccardiologynj/

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



The Extradimensional Madness of the Prophets” is a compelling discussion of the modern American church


News Image

“Puppies and Napalm: The Extradimensional Madness of the Prophets”: a spiritual call to arms that offers a reminder of God’s true intentions for creation. “Puppies and Napalm: The Extradimensional Madness of the Prophets” is the creation of published author Jason Malott.

Malott shares, “Long ago, prophets spoke the word of God to the people. These prophets were full of zeal and sometimes madness. God got as creative as he could with this eccentric bunch. He had some of them lay on their side in the mud for days; some of them he showed visions of alien spacecrafts and creatures with eyes all over their body. Their words crossed other dimensions and predicted future events.

“He spoke through them to a nation that had lost its way.

“Just a little like us today. Can I get an amen?

“This book is written to the church of America, the lost, shinning beacon of hope, the great imperialist empire once called a “Christian nation” that never was.

“This book is to everyone who feels like something is wrong. Something is very, very wrong with us. This book is for those who are tired of a group of people trying to scare us into believing in a god that wants to burn us. What else should I call it?

“Puppies and Napalm.”

Published by Christian Faith Publishing, Jason Malott’s new book brings an encouraging message of hope to followers of Christ.

Malott takes aim at the challenges facing the church through the fear-based teachings of a vengeful God in a manner that will resonate with many.

Consumers can purchase “Puppies and Napalm: The Extradimensional Madness of the Prophets” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Puppies and Napalm: The Extradimensional Madness of the Prophets,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

PDUFA and BsUFA Reauthorization Developments Webinar on Nov. 8, 2022


PDUFA and BsUFA Reauthorization Developments

What Regulatory, Compliance, and Quality Professionals Need to Know

Tuesday, Nov. 8, 2022, 1:30 p.m.–3:00 p.m. EST

https://wcg.swoogo.com/pdufa-and-bsufa

After challenging debates, Congress passed a bare-bones reauthorization of the prescription drug and biosimilars user fee programs.

What does this package contain? What did Congress leave out? What does the future hold for the accelerated approval and clinical trial diversity drug- and biologic-related riders? What does this mean for biosimilar interchangeability?

Jessica Greenbaum, counsel in King & Spalding’s FDA and Life Sciences practice and former regulatory counsel in the FDA’s Office of Therapeutic Biologics and Biosimilars, will walk attendees through the potential fate of the remaining provisions so they will be ready when, or if, the initiatives take effect.

Ms. Greenbaum will provide:


  • An overview of the bare-bones user fee package Congress enacted on Sept. 30, 2022
  • A deeper understanding of the key drug- and biologics-related riders that accompanied the original House and Senate bills, including those related to accelerated approval and diversity in clinical trials
  • Insight into the potential consequences and impacts of these provisions, including how the proposal to amend the first interchangeable exclusivity provisions could facilitate competition
  • A look at what the future holds, with congressional debate only deferred, not canceled

Congress has only two months to revive and resolve these issues before new legislators, take their seats in January. Now is the time to prepare for the inevitable changes.

Webinar Details

PDUFA and BsUFA Reauthorization Developments

What Regulatory, Compliance and Quality Professionals Need to Know

Tuesday, Nov. 8, 2022, 1:30 p.m.–3:00 p.m. EST

https://wcg.swoogo.com/pdufa-and-bsufa

Price:

$287

Easy Ways to Order:

Online: https://wcg.swoogo.com/pdufa-and-bsufa

By phone: 888.838.5578 or 703.538.7600

About WCG FDAnews:

WCG FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on WCG FDAnews’ newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations. Learn more at fdanews.com.

Share article on social media or email:

Joseph Simone Says Medical Real Estate Developers Should Locate Properties With Equity In Mind


Montefiore Hospital’s 11-floor, 280,000-square-foot ambulatory care center at Simone’s Hutchinson Metro Center.

“Proximity to mass transit stations and bus lines are essential to creating an inclusive healthcare industry,” said Joe Simone, President of Simone Development Companies.

Joseph Simone of Simone Development Companies says that medical real estate developers should choose locations accessible to a broad range of income levels to promote healthcare inclusion.

“The site-location process should consider accessibility for low-income, as well as handicapped individuals who rely on public transportation. Proximity to mass transit stations and bus lines are essential to creating an inclusive healthcare industry,” said Joe Simone, President of Simone Development Companies.

Mass-transit-reliant consumers will gain increasing healthcare options as the Metro-North Railroad opens new train stations in the Bronx. Simone Development Companies’ Hutchinson Metro Center sits next to a future Metro-North train station in Morris Park that will provide easy access from the Hell Gate and New Haven train lines.

Some of the neighborhoods near the future rail stations have large populations of medically underserved communities. According to a New York City Community Health Profile, the neighborhood surrounding the future Hunts Point Metro-North station ranks first in New York City for adults who forego needed medical care.

The Hutchinson Metro Center’s 42-acre campus is anchored by Montefiore Hospital’s 11-floor, 280,000-square-foot ambulatory care center. The patient-focused and highly streamlined facility offers more than two dozen adult and pediatric medical specialties, including cardiology, urology, and diabetes.

“The Hutchinson Metro Center is helping to deliver healthcare equity to the Bronx and surrounding communities. Simone Development Companies will continue developing this campus to optimally serve the healthcare needs of all Bronx residents,” said Patricia Simone, principal and president of the Simone Management Group.

Simone Development Companies is a full-service real estate investment company specializing in the acquisition and development of healthcare, mixed-use, office, industrial, retail, and residential properties. Headquartered at the Hutchinson Metro Center, it boasts a portfolio of over 7 million square feet throughout the Bronx, Manhattan, Queens, Long Island, Westchester County, Orange and Fairfield Counties and New Jersey. With services spanning acquisition, development, construction, finance, asset management, accounting, leasing and property management, Simone Development Companies is set apart by its vertically integrated management team, long-term asset ownership and its pursuit of visionary development.

Share article on social media or email:

VHS Learning Reveals New Commitment to CSforALL Movement


News Image

We believe all students should have access to computer science education, regardless of their geographic location or economic circumstances. It is our honor to be part of the movement to help ensure high school students have equitable access to great CS courses.

At the 2022 CSforALL Summit, VHS Learning announced its plans to further expand student access to computer science education. The nonprofit revealed that it will offer free online computer science courses to fifty high school students in rural or underserved high schools. The nonprofit has also created a new beginner’s course on Python, one of the fastest growing computer programming languages.

A total of 180 organizations, up from 136 last year, disclosed commitments during the CSforALL summit, which took place October 19-21, 2022, in Memphis, Tennessee. CSforALL commitments are new, specific, and measurable actions aimed at advancing the goal of rigorous and inclusive computer science education for all U.S. youth. The commitments grow support and momentum for a sustainable K-12 computer science education system in and out of school. VHS Learning has been making annual commitments since the inception of the national CSforALL movement.

In addition to free enrollment in VHS Learning online computer science courses, sponsored students will receive all necessary course materials, and a student orientation. All VHS Learning’s computer science courses are led by teachers certified in their subject area.

Computer science courses in VHS Learning’s high school course catalog include:

  • AP® Computer Science A
  • AP® Computer Science Principles
  • Architectural CAD
  • Creative Programming with Scratch
  • Cybersecurity
  • Introduction to Computer Science Principles
  • Java Programming
  • Python Programming
  • Video Game Design
  • Web Design

Python Programming is a new addition to the VHS Learning course catalog. Students will explore two integrated development environments (IDEs), Replit and EarSketch, as they learn fundamental Python programming concepts, principles, and skills. As a final project, students will use their newly-acquired skills to develop a custom application in an area of interest.

“As with all VHS Learning computer science courses, our new Python Programming course uses engaging and creative activities to make learning fun,” said Carol DeFuria, President & CEO of VHS Learning. “This course and our sponsorship of student enrollments are the latest in our nonprofit’s annual commitment to the CSforALL movement. We believe all students should have access to computer science education, regardless of their geographic location or economic circumstances. It is our honor to be part of the movement to help ensure high school students have equitable access to great CS courses.”

About VHS Learning

VHS Learning is a nonprofit organization with over 26 years of experience providing world-class online programs to students and schools everywhere. Offering more than 300 unique online courses for high school credit, including 26 AP® courses, credit recovery, and enrichment courses, VHS Learning is accredited by Middle States Association Commission on Elementary and Secondary Schools (MSA-CESS), Accrediting Commission for Schools, Western Association of Schools and Colleges (ACS WASC), and Cognia. Courses are approved for initial eligibility by NCAA. For more information about VHS Learning please visit https://www.vhslearning.org/ and follow on Twitter at @VHSLearning.

# # #

Share article on social media or email:

Foria Announces New Executive Team To Lead Brand Growth


This week, Jon Brandon, CEO & Co-Founder of plant-based sexual wellness company Foria, is excited to introduce a new executive team, strategically assembled to fuel the next phase of the company’s growth. Foria welcomes Liz Dolinski as Chief Marketing Officer who will work alongside Gemma DePalma (newly promoted to Chief Operating Officer).

The new executive team will lead the brand’s next chapter of national and international growth through a dynamic omnichannel strategy that includes both e-commerce and wholesale. They’ll also oversee innovation, product development, internal company evolution, strategic partnerships, and more.

As CMO, Liz Dolinski will lead Foria’s go-to-market strategy, including brand vision, creative direction, and content, as well as wholesale and direct-to-consumer streams. A seasoned marketing executive, Liz has led multiple emerging brands in making the leap from startup to fully scaled company. Prior to Foria, Liz was Chief Growth Officer at the DTC sleepwear brand Lunya, where she was responsible for all revenue-driving departments. Liz joined Foria based on her belief that the brand’s products provide life-changing experiences for its customers –– she brings a wealth of experience across marketing strategy, ecommerce, advertising, retail marketing, partner marketing, budgets, contracting, and more.

Additionally, Gemma DePalma has been promoted to Chief Operating Officer. She joined the Foria team in 2019 as Chief Supply Chain Officer, managing and maintaining executive leadership over the full supply chain team. In her new COO role, Gemma will be responsible for designing and implementing policies to promote company culture and vision. She will harness her expertise and deep understanding of Foria’s values to achieve its ambitious goals while maintaining the brand’s commitment to clean ingredients, sustainable packaging, and accessible education.

Kiana Reeves, who has been integral to Foria’s success over the past five years, will shift to Chief Content Officer. A somatic sex educator, certified sexological bodyworker, pelvic health practitioner and certified doula, Reeves has been practicing in the field of sexual wellness and female reproductive health for over 10 years and has a lifelong passion for sexual wellness and plant-based medicine. Her commitment to promoting open dialogue around pleasure and helping people feel more connected to their own sexual experiences and their bodies ultimately led her to become a voice for Foria. She harnesses her certifications and qualifications to help drive Foria’s content and brand education.

Jon is committed to building socially responsible companies that create innovative products designed to make meaningful impacts in people’s lives. That commitment led him to co-found Foria in 2014. Drawing inspiration from history’s celebration of cannabis and other plants as aids for intimacy, Jon’s drive and passion have spearheaded the creation of many of Foria’s life-changing offerings, including their bestselling Awaken arousal oil and Sex Oil. With these changes to the executive team, Jon is paving the way for Foria’s continued growth as a leader in the sexual wellness space. Discussing the new executive team, Jon shared:

“As Foria evolves into its ‘scale-up’ phase, I’m genuinely excited to be surrounded by such a talented executive team. Liz is a true scale-hacker, who brings a wealth of relevant growth expertise and Gemma is a leader who will organize our team for operational growth. These changes together with Kiana’s new focus will serve our continued mission of providing life-changing, plant-based sexual wellness products that close the pleasure gap and address the universal experiences that women and people who love them encounter across their lifespan.”

Foria’s products are available for nationwide shipping via http://www.foriawellness.com as well as at Ulta, Nordstrom, Neiman Marcus, Saks Fifth Avenue, Thrive Market and many more.

For media inquiries, please contact RVD Communications at mailto:press@foriawellness.com.

About Foria

Foria is an innovative sexual wellness company that makes life-changing, all-natural, organic formulas for intimacy, period relief and daily wellbeing. Rooted in the belief that pleasure is your nature, Foria sets the standards in the sexual wellness space for clean, innovative, and highly effective formulas. With award-winning products, Foria supports intimate experiences across every stage of life to bring more pleasure to more people.

Foria believes that pleasure and connection sit at the heart of wellbeing. Designed to fill long standing gaps in the sexual wellness market, Foria’s products are specifically designed for the female body. Guided by the wisdom of plants, Foria intentionally selects botanicals to solve real needs and deliver meaningful results. Foria’s products are sustainably made from seed to shelf, with a commitment to organic & regeneratively farmed ingredients and low impact packaging. Every product is made domestically in the USA, with mother nature in mind every step of the way.

Foria products go through rigorous development and ingredient testing to meet a standard not often seen in the industry – and it is one of the only brands that provides transparent third-party testing reports for all of its ingredients. During this process, if any ingredient doesn’t meet Foria’s standards, it is reformulated or sourced from a different supplier. The brand also provides a Certificate of Analysis (COA) for every product they sell, furthering its commitment to the health and wellness of its community.

Most recently, as part of Foria’s mission to close the pleasure gap and make pleasure and wellness accessible to all, the brand has expanded its line to include botanical CBD-Free products, including an arousal oil with botanicals and a sensual breast oil.

###

Share article on social media or email: